Patents by Inventor Richard Wooster

Richard Wooster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10624967
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: April 21, 2020
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Publication number: 20200113877
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Publication number: 20200085960
    Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 19, 2020
    Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
  • Publication number: 20200078468
    Abstract: Conjugates of an active agent attached to a neurotensin receptor-binding targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 12, 2020
    Inventors: Mark T. Bilodeau, Mary Simcox, Brian H. White, Sudhakar Kadiyala, Richard Wooster
  • Patent number: 10548881
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: February 4, 2020
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Publication number: 20190365913
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker, and particles comprising such conjugates have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: February 3, 2017
    Publication date: December 5, 2019
    Inventors: Richard Wooster, Sudhakar Kadiyala, Mark T. Bilodeau
  • Publication number: 20190350940
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
  • Patent number: 10342801
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 9, 2019
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
  • Patent number: 10322191
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: June 18, 2019
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Patent number: 10322137
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: June 18, 2019
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Mark T. Bilodeau, Benoit Moreau, Adam H. Brockman, Kristan Meetze, Kerry Whalen, Richard Wooster, Rossitza G. Alargova
  • Publication number: 20190085034
    Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 21, 2019
    Inventors: Richard Wooster, Mark T. Bilodeau, Sudhakar Kadiyala
  • Publication number: 20190054072
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: February 23, 2017
    Publication date: February 21, 2019
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Publication number: 20180296685
    Abstract: Targeted constructs and pharmaceutical formulations thereof, comprising at least one conjugate of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via an internal linker moiety have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. The internal linker may comprise a silicon-heteroatom core. Methods of making the targeted constructs and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Richard Wooster, Mark T. Bilodeau
  • Publication number: 20180243318
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: August 30, 2018
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
  • Publication number: 20180221499
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: October 28, 2016
    Publication date: August 9, 2018
    Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
  • Publication number: 20180221503
    Abstract: The present invention relates to cancer immunotherapy. Conjugates and nanoparticles comprising active agents that can elicit a cancer specific immune response are provided. The conjugates comprise one or more targeting moieties that are connected to the active agents. Nanoparticles comprising the conjugates of the present invention are also provided to increase the delivery of the conjugates, and increase immunogenicity and lower toxicity.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Inventors: Sudhakar Kadiyala, Donna T. Ward, Richard Wooster
  • Publication number: 20180186823
    Abstract: The present teachings relate to compounds and compositions comprising a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or any moiety which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof. The platinum (IV) complex may comprise at least one active agent.
    Type: Application
    Filed: June 22, 2016
    Publication date: July 5, 2018
    Inventors: Sudhakar Kadiyala, Benoît Moreau, Mark T. Bilodeau, Kerry Whalen, Sukhjeet Singh, Richard Wooster, Charles-Andre Lemelin
  • Patent number: 9937187
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: April 10, 2018
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Mark T. Bilodeau, Benoît Moreau, Adam H. Brockman, Kristan Meetze, Kerry Whalen, Richard Wooster, Rossitza G. Alargova
  • Publication number: 20180021454
    Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: September 5, 2017
    Publication date: January 25, 2018
    Inventors: Mark T. Bilodeau, Sudhakar Kadiyala, Rajesh R. Shinde, Brian H. White, Richard Wooster, Benoît Moreau
  • Publication number: 20180008614
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.
    Type: Application
    Filed: September 21, 2017
    Publication date: January 11, 2018
    Inventors: Mark T. Bilodeau, Benoît Moreau, Adam H. Brockman, Kristan Meetze, Kerry Whalen, Richard Wooster, Rossitza G. Alargova